Figure 2.

PDGFB-Driven Gliomas in the N/tv-a;Arf^−/− Mouse Model Display Hypoxia and Vessel Hyperproliferation

(A and B) (A) Glioma sections were immunostained for CD31 (blue), fluorescein isothiocyanate (FITC)-conjugated lectin (green), and the hypoxic marker pimonidazole (PIMO; red). (B) Graph shows morphometric analysis of hypoxic areas (n = 3–5). Scale bars, 100 μm.

(C and D) (C) Glioma sections were immunostained for podocalyxin (green) and Ki67 (red). (D) Graph depicts quantification of podocalyxin⁺Ki67⁺ vessels (n = 3). Scale bars, 100 μm.

(E and F) (E) Glioma sections were immunostained for CD31 (blue), FITC-conjugated lectin (green), and the pericyte marker α-SMA (red). (F) Graph displays quantification of α-SMA (n = 3–5). Scale bars, 100 μm.

(G and H) (G) Glioma sections were immunostained for OLIG2 (blue), FITC-conjugated lectin (green), and α-SMA (red). (H) Graph shows analysis of α-SMA⁺ sheets associated with vessels. Scale bars, 100 (left panel) and 50 (right panel) μm.

(I) Glioma sections were immunostained for podocalyxin (blue), microglia marker IBA1 (green), and α-SMA (red). Scale bars, 100 (left panel) and 50 μm (right panel).

Statistical analysis: one-way ANOVA (A–F) and student's t test (G and H) were used: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; * indicates significance (A–F) compared with grade II-like tumors and (H) between α-SMA⁺ sheets associated and non-associated with vessels; ^#p < 0.05; ^# indicates significance between grade III- and grade IV-like tumors.